Obesity Management

Once-weekly tirzepatide may be an alternative to daily hormone shots in patients with congenital generalized lipodystrophy.

The American Heart Association’s 2025 statistical update confirms cardiovascular diseases claim more US lives than all forms of cancer and accidental deaths.

Enobosarm led to a statistically significant benefit in the protection of lean mass in patients with overweight or obesity receiving semaglutide.

Subcutaneous amycretin achieved up to a 22.0% weight loss over 36 weeks, with a consistent safety profile to other incretin-based therapies.

Approximately 2.0% of commercially insured individuals with obesity, but not diabetes, initiated semaglutide within 6 months of diagnosis.

Semaglutide 7.2 mg achieved statistically significant and superior weight loss at 72 weeks versus placebo, hitting the Phase 3b trial's primary endpoint.

Medicare has selected 15 additional drugs to negotiate prices directly with participating drug companies, including semaglutide (Ozempic).

Hosts are joined by a registered dietitian and practicing endocrinologist to discuss dietitians' role in managing patients receiving incretin therapies.

A new study highlights notable obesity-associated disruptions of iron metabolism, with higher hemoglobin and serum ferritin levels in pre-obese and obese cohorts.

Our Endocrinology Month in Review for December 2024 highlights recent headlines in diabetes and endocrinology and 4 new episodes of Diabetes Dialogue.

A systematic review and meta-analysis of observational real-world data finds nearly half of patients who begin a GLP-1 RA will discontinue within a year.

In this episode, hosts discuss a slight dip in US obesity rates, the use of inhaled insulin, and the benefit of mifepristone for HbA1c reduction.

A list recapping our most popular endocrinology coverage from the past year.

To celebrate the close of 2024, we're recapping the 10 most popular approval articles across the HCPLive Network of brands.

Glycemic control continues to be a major risk factor for diabetic retinopathy, while overweight, obesity, and hypertension are growing in prevalence.

In this episode, hosts discuss the efficacy of MariTide for obesity, a head-to-head comparison of semaglutide vs. tirzepatide, and concerns about GLP-1 agonist compounding.

Yehuda Handelsman, MD reflects on the WCIRDC 2024’s comprehensive approach to advancing cardiometabolic care through multidisciplinary collaboration.

Tirzepatide's approval marks the first and only prescription medicine available for adults with moderate-to-severe obstructive sleep apnea and obesity.

CagriSema, a fixed dose of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved statistically significant weight loss after 68 weeks versus placebo.

Laurence Sperling, MD described the evolving role of cardiologists in obesity care, particularly with the increasing adoption of therapies such as GLP-1 agonists.

Laurence Sperling, MD shares insights into a multi-disciplinary approach to the management of obesity from the perspective of a cardiologist.

Schafer Boeder, MD describes the potential role and safety of adjunctive therapy, including SGLT2 inhibitors and GLP-1 agonists, for patients with T1D.

Real-world data from 18,710 MASH patients highlight the impact of comorbidities, biomarkers, and region on mortality, with 70% of deaths CVD-related.

Matthew J. Budoff, MD discusses the effects of obesity and cardiometabolic complications in the contemporary management of type 1 diabetes.

Elevated blood insulin levels and insulin resistance each contributed to an elevated risk of colorectal cancer, a new study finds.